Our results show that in OI patients in the absence of these pro-osteoclastogenic factors, the secretion of CK-BB is significantly elevated at 3 μmol/L of neridronate compared with 0.3 and 1 μmol/L neridronate (p = 0.007); however, the differences were not statistically significant compared with the untreated condition. This evidence concerns the gene CKB and osteogenesis imperfecta.